WuXi Biologics And Hangzhou DAC Signed Research Service Agreement With Aadi Bioscience On Three Novel ADCs

WuXi Biologics a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it and Hangzhou DAC Biotechnology CO., LTD. (Hangzhou DAC) have signed a research service agreement with Aadi Bioscience, Inc. for a three-asset portfolio of preclinical next-wave antibody-drug conjugates (ADCs).

These assets were discovered through the collaborative efforts of WuXi Biologics and Hangzhou DAC, utilizing the innovative antibody discovery platform provided by WuXi Biologics and advanced linker-payload technology provided by Hangzhou DAC. Per the terms of the agreement, Aadi will pay WuXi Biologics and Hangzhou DAC upfront payments of $44M for the three assets. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265M, cumulative commercial milestone payments of up to $540M and single-digit royalties of sales.

“Leveraging our advanced antibody discovery service, we’re glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers,” said Dr. Chris Chen, CEO of WuXi Biologics. “This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and Hangzhou DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide.”

“I’m thrilled to announce our partnership with WuXi Biologics and Hangzhou DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer,” said David Lennon, PhD, President and CEO of Aadi Bioscience.

“We are thrilled to announce this strategic collaboration with Aadi and WuXi Bio,” said Robert Y. Zhao, founder and CEO of Hangzhou DAC. “Aadi’s in-depth knowledge of precision oncology and expertise in clinical development will provide robust support for future development of these three ADC programs. Meanwhile, we look forward to advancing our strategic collaboration with WuXi Bio and developing more innovative ADCs.”